Resolve Therapeutics to Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology


SEATTLE–(BUSINESS WIRE)–Resolve Therapeutics, an immuno-therapeutics company developing first-in-class, safe, targeted therapies for underserved autoimmune diseases, today announced that an oral presentation on the Company’s lead product candidate, RSLV-132, will be presented at the 2019 European League Against Rheumatism (EULAR) European Congress of Rheumatology in Madrid, Spain. Presentation Details:Title: “Effect of RSLV-132 on Fatigue in Patients with Primary Sjögren’s Syndrome – Results….